Company research
BIODESIX INC
CIK 1439725Updated Sep 26, 2026
SecurityBDSX · NASDAQ · equity
BDSX price & chart
Loading TradingView…
NASDAQ:BDSX on TradingView ↗About the company
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including the Nodify Lung® Nodule Risk Assessment test and the IQLung® Cancer Treatment Guidance test, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
In the news
Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference ↗
Recent filings
4 filing
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by Soleus Capital Master Fund, L.P. regarding BIODESIX INC
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 87,476,000Source | 97,244,000Source | 99,096,000Source | 92,906,000Source |
| Property, Plant and Equipment, NetUSD | 24,817,000Source | 27,828,000Source | 27,867,000Source | 5,848,000Source |
| GoodwillUSD | 15,031,000Source | 15,031,000Source | 15,031,000Source | 15,031,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 3,883,000Source | 5,874,000Source | 7,911,000Source | 9,797,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 18,987,000Source | 26,245,000Source | 26,284,000Source | 43,088,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 9,036,000Source | 8,603,000Source | 7,679,000Source | 5,065,000Source |
| Assets, CurrentUSD | 32,518,000Source | 39,484,000Source | 39,683,000Source | 53,334,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,997,000Source | 1,767,000Source | 1,745,000Source | 2,973,000Source |
| Other Assets, NoncurrentUSD | 8,230,000Source | 7,260,000Source | 6,859,000Source | 5,923,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 89,941,000Source | 76,368,000Source | 94,516,000Source | 72,300,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 8,000Source | 145,000Source | 96,000Source | 78,000Source |
| Additional Paid in CapitalUSD | 495,289,000Source | 483,228,000Source | 424,050,000Source | 387,948,000Source |
| Retained Earnings (Accumulated Deficit)USD | -497,762,000Source | -462,497,000Source | -419,566,000Source | -367,420,000Source |
| Stockholders' Equity Attributable to ParentUSD | -2,465,000Source | 20,876,000Source | 4,580,000Source | 20,606,000Source |
| Liabilities and EquityUSD | 87,476,000Source | 97,244,000Source | 99,096,000Source | 92,906,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 17,436,000Source | 14,317,000Source | 33,416,000Source | 22,839,000Source |
| Operating Lease, Liability, CurrentUSD | 1,364,000Source | 719,000Source | 252,000Source | 1,543,000Source |
| Accounts Payable, CurrentUSD | 3,080,000Source | 2,194,000Source | 2,929,000Source | 1,685,000Source |
| Operating Lease, Liability, NoncurrentUSD | 24,039,000Source | 24,828,000Source | 25,163,000Source | 5,254,000Source |
| Other Liabilities, NoncurrentUSD | 1,021,000Source | 815,000Source | 712,000Source | 558,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 11,033,000Source | 10,064,000Source | 7,710,000Source | 8,218,000Source |
| Long-term DebtUSD | 50,006,000Source | 40,026,000Source | 40,078,000Source | 30,127,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -35,265,000Source | -42,931,000Source | -52,146,000Source | -65,447,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,139,000Source | 6,638,000Source | 5,373,000Source | 5,961,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 531,000Source | 1,811,000Source | 4,718,000Source | 1,501,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -23,271,000Source | -48,649,000Source | -22,870,000Source | -44,972,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -403,000Source | -3,440,000Source | -23,062,000Source | -3,534,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 259,000Source | 3,230,000Source | 22,919,000Source | 3,298,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 16,417,000Source | 52,050,000Source | 29,129,000Source | 58,882,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | -817,000Source | -445,000Source | -188,000Source | -33,000Source |
| Repayments of Long-term DebtUSD | 21,000Source | 51,000Source | 49,000Source | 28,604,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -7,257,000Source | -39,000Source | -16,803,000Source | 10,376,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 19,075,000Source | 26,332,000Source | 26,371,000Source | 43,174,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,398,000Source | 7,024,000Source | 3,994,000Source | 1,009,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 4,139,000Source | 6,638,000Source | 5,373,000Source | 5,961,000Source |
| Amortization of Intangible AssetsUSD | 2,028,000Source | 2,008,000Source | 1,983,000Source | 1,975,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | -248,000Source | — | -6,981,000Source |
| GoodwillUSD | 15,031,000Source | 15,031,000Source | 15,031,000Source | 15,031,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 100,000Source | 200,000Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | 107,000Source | 238,000Source | 44,000Source | 81,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 7,716,000Source | 8,258,000Source | — | — |
| Inventory Write-downUSD | 49,000Source | 22,000Source | 166,000Source | 906,000Source |
| Net Income (Loss) Attributable to ParentUSD | -35,265,000Source | -42,931,000Source | -52,146,000Source | -65,447,000Source |
| Nonoperating Income (Expense)USD | -7,392,000Source | -8,433,000Source | — | — |
| Operating ExpensesUSD | 116,372,000Source | 105,821,000Source | 90,429,000Source | 88,799,000Source |
| Operating Lease, ExpenseUSD | 2,300,000Source | 2,300,000Source | 4,300,000Source | 2,600,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -10,804,000Source | -14,860,000Source |
| Proceeds from Issuance of Common StockUSD | 7,320,000Source | 55,625,000Source | 28,126,000Source | 59,538,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 25,000Source | 91,000Source | 269,000Source |
| Provision for Loan, Lease, and Other LossesUSD | 180,000Source | 887,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 88,499,000Source | 71,323,000Source | 49,087,000Source | 38,212,000Source |
| Selling, General and Administrative ExpenseUSD | 87,545,000Source | 80,451,000Source | 67,387,000Source | 61,462,000Source |
| Operating Income (Loss)USD | -27,873,000Source | -34,498,000Source | -41,342,000Source | -50,587,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -10,804,000Source | -14,860,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -35,265,000Source | -42,931,000Source | -52,146,000Source | -65,447,000Source |
| Earnings Per Share, BasicUSD per share | -4.67Source | -0.33Source | -0.64Source | -1.55Source |
| Earnings Per Share, DilutedUSD per share | -4.67Source | -0.33Source | -0.64Source | -1.55Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 7,551,000Source | 129,670,000Source | 82,113,000Source | 42,103,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 7,551,000Source | 129,670,000Source | 82,113,000Source | 42,103,000Source |
| Interest Expense (non-operating)USD | 7,716,000Source | 8,258,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,028,000Source | 2,008,000Source | 1,983,000Source | 1,975,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 5,670,000Source | 5,773,000Source | 3,328,000Source | 3,597,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Interest ExpenseUSD | 7,716,000Source | 8,258,000Source | 9,536,000Source | 8,072,000Source |
| Nonoperating Income (Expense)USD | -7,392,000Source | -8,433,000Source | — | — |
| Operating ExpensesUSD | 116,372,000Source | 105,821,000Source | 90,429,000Source | 88,799,000Source |
| Operating Lease, ExpenseUSD | 2,300,000Source | 2,300,000Source | 4,300,000Source | 2,600,000Source |
| Research and Development ExpenseUSD | 12,001,000Source | 9,559,000Source | 9,988,000Source | 13,102,000Source |
| Selling and Marketing ExpenseUSD | 7,562,000Source | 7,574,000Source | — | — |
Filing attachments
bdsx-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 bdsx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, August 5, 2026 - Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its …
Read attachment ↗bdsx-ex99_1.htm · 8-K · 2026-05-04
EX-99.1 2 bdsx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biodesix Announces First Quarter 2026 Results and Highlights Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, May 4, 2026 - Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financ…
Read attachment ↗bdsx-ex99_1.htm · 8-K · 2026-02-26
EX-99.1 2 bdsx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, February 26, 2026 - Biodesix, Inc. (Nasdaq: BDSX), a leading dia…
Read attachment ↗bdsx-ex99_1.htm · 8-K · 2025-11-03
EX-99.1 2 bdsx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biodesix Announces Third Quarter 2025 Results and Highlights Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, November 3, 2025 - Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announce…
Read attachment ↗d45697dex991.htm · 8-K · 2025-09-11
EX-99.1 2 d45697dex991.htm EX-99.1 EX-99.1 Biodesix Announces One-for-Twenty Reverse Stock Split Louisville, CO September 11, 2025 - Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company’s common stock will continue to tr…
Read attachment ↗bdsx-ex99_1.htm · 8-K · 2025-08-07
EX-99.1 2 bdsx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biodesix Announces Second Quarter 2025 Results and Highlights Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, August 7, 2025 - Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today anno…
Read attachment ↗